Physician
Children's Healthcare Associates, LLP
Children's Healthcare Associates, LLP was paid $3.77M by Medicaid between Oct 2018 and Dec 2024, across 50 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoCHILDREN'S HEALTHCARE ASSOCIATES, LLP
AMARILLO, TX 79106
AMARILLO, TX 79106
33aNPI1831226430assigned 02/28/2007
33bProvider typePediatrics Physician
28Total paid$3.77M
24GClaims136,364
24DCodes billed50
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#121 of 1,136
Median peer was paid$329K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24 | $188.16 | |
| 2020 | 3,958 | $93K | |
| 2021 | 36,298 | $935K | |
| 2022 | 35,725 | $1.07M | |
| 2023 | 35,722 | $993K | |
| 2024incomplete | 24,637 | $678K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 18,181 | 14,845 | $893K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 16,017 | 13,945 | $570K |
| 87428 | 11% | 9,297 | 7,818 | $422K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.5% | 4,826 | 4,717 | $358K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8.6% | 4,664 | 4,276 | $324K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.4% | 16,046 | 6,330 | $166K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.3% | 2,048 | 2,011 | $162K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.4% | 10,057 | 8,417 | $127K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.3% | 1,581 | 1,477 | $124K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.2% | 2,932 | 2,684 | $84K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 1,512 | 1,259 | $56K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.4% | 6,448 | 4,396 | $51K |
38 more codes
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.3% | 565 | $50K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 3,913 | $49K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 988 | $48K |
| 87634 | 1.3% | 834 | $48K | |
| 92558 | 1.2% | 6,878 | $47K | |
| 99429 | 1.2% | 2,032 | $44K | |
| 87807 | <1% | 3,374 | $34K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 89 | $28K |
| 90461 | <1% | 4,790 | $26K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 220 | $18K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,105 | $12K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 25 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 493 | $5K |
| 99383 | <1% | 54 | $4K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 458 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 191 | $2K |
| 99382 | <1% | 26 | $2K | |
| 96160 | <1% | 1,194 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 15 | $957.16 |
| 81002 | <1% | 202 | $563.56 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 17 | $413.80 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $251.39 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 160 | $227.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 54 | $50.84 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 143 | $18.85 |
| 90671 | <1% | 1,018 | $0.48 | |
| 90744 | 0% | 1,492 | $0.00 | |
| 90698 | 0% | 3,136 | $0.00 | |
| 90680 | 0% | 2,193 | $0.00 | |
| 90686 | 0% | 2,245 | $0.00 | |
| 90647 | 0% | 53 | $0.00 | |
| 90696 | 0% | 14 | $0.00 | |
| 90619 | 0% | 17 | $0.00 | |
| 90670 | 0% | 2,491 | $0.00 | |
| 90710 | 0% | 812 | $0.00 | |
| 90633 | 0% | 1,175 | $0.00 | |
| 99188 | 0% | 250 | $0.00 | |
| 90700 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWERNER, CARMEN (MEDICAL DIRECTOR)